Rafael Henrique | Lightrocket | Getty Images
British pharmaceutical giant GSK on Wednesday committed to investing at least $30 billion in U.S. research and developing (R&D) and manufacturing over the coming five years.
The investment includes $1.2 billion toward advanced manufacturing, AI and advanced digital technologies to deliver “next-generation biopharma factories and laboratories in the United States,” the drug maker said.
The investment commitment comes as President Donald Trump is in the U.K. for a three-day state visit.
“This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both,” GSK CEO Emma Walmsley said in a statement.
“Today, we are committing to invest at least $30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country,” she added.
This is a developing story. Please check back for updates.
